Recurrence Score Result

For your patients with HR+, HER2-, early-stage, invasive breast cancer

The Oncotype DX Breast Recurrence Score^® report provides three points of clarity to aid in treatment decisions as to whether adjuvant chemotherapy is needed or not for node-negative and node-positive (N1: up to 3 positive lymph nodes), hormone receptor-positive, HER2-negative, early-stage breast cancer patients.

3 pieces of information provided by the test

Recurrence Score^® result

This number, between 0 and 100, is calculated by measuring the activity of specific genes in the breast cancer tissue. The Recurrence Score result is used to predict the risk of the breast cancer returning at a distant site and whether chemotherapy may help reduce the risk.^1-5

Distant recurrence risk^a

This percentage indicates the risk that the breast cancer will come back somewhere else in the body, “distant recurrence,” within 9 years (node-negative)^1,6 or 5 years (node-positive)^4,7,8 when treated with hormonal therapy alone for 5 years.

Absolute chemotherapy benefit^a

This percentage indicates the benefit expected for the Recurrence Score group from adding chemotherapy to hormonal therapy in order to reduce the risk of cancer recurrence or death.^{2-4, 6-8}

Explore the patient reports

NODE-NEGATIVE

NODE-POSITIVE

START REPORT GUIDE

START REPORT GUIDE

START REPORT GUIDE

1 2 3

START REPORT GUIDE

START REPORT GUIDE

1 2

Further Understanding the Results: Node-Negative Patients

Recurrence Score Result

Patients with a Recurrence Score result of 0-25 generally do not benefit from the addition of chemotherapy to endocrine therapy.^2,3,6

For patients under 50 years of age there is some chemotherapy benefit (in terms of DRFI) for those with Recurrence Score result 16 and above.⁶

Patients with Recurrence Score results 26–100 significantly benefit from the addition of chemotherapy to endocrine therapy.^2,3

Further Understanding the Results: Node-Positive Patients

Recurrence Score Result

Post-menopausal patients with a Recurrence Score result of 0–25 do not benefit from the addition of chemotherapy to endocrine therapy.^4,7

Pre-menopausal patients with Recurrence Score results of 0-25 have a 2.4% benefit (in terms of DRFI) from the addition of chemotherapy to endocrine therapy.⁸

All patients with Recurrence Score results 26-100 significantly benefit from the addition of chemotherapy to endocrine therapy.⁴

ABBREVIATIONS

REFERENCES
Paik et al. N Engl J Med. 2004.

Paik et al. J Clin Oncol. 2006.

Geyer et al. NPJ Breast Cancer. 2018.

Albain et al. Lancet Oncol. 2010.

Dowsett et al. J Clin Oncol. 2010.

Sparano et al. N Engl J Med. 2018.

Kalinsky et al. NEJM. 2021.

Kalinsky et al. SABCS 2021.

Contact Us

GET IN TOUCH

Recurrence Score Result

For your patients with HR+, HER2-, early-stage, invasive breast cancer

3 pieces of information provided by the test

Recurrence Score^® result

Distant recurrence risk^a

Absolute chemotherapy benefit^a

Explore the patient reports